Insider · CIK 0001918845

Doyle Mittie

Reports to the SEC for 3 companies · WAYNE, PA

sec.gov

Transactions

Companies

Filings

CIK

0001918845

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-28	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+679 sh	$8.04	+$5,459.16	52,455
2026-08-28	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−679 sh	—	—	113,734
2026-08-28	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−679 sh	$20.00	−$13.6K	51,776
2026-08-17	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,000 sh	$12.65	+$12.7K	52,776
2026-08-17	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−1,000 sh	$20.00	−$20K	51,776
2026-08-17	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,000 sh	—	—	123,750
2026-08-10	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−679 sh	$20.00	−$13.6K	51,776
2026-08-10	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−679 sh	—	—	114,413
2026-08-10	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+679 sh	$8.04	+$5,459.16	52,455
2026-07-27	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,000 sh	—	—	124,750
2026-07-27	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,000 sh	$12.65	+$12.7K	52,776
2026-07-27	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−1,000 sh	$20.00	−$20K	51,776
2026-06-30	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,779 sh	$8.04	+$14.3K	56,430
2026-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,779 sh	—	—	115,092
2026-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−2,875 sh	—	—	125,750
2026-06-30	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−4,654 sh	$20.00	−$93.1K	51,776
2026-06-30	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+2,875 sh	$12.65	+$36.4K	54,651
2026-06-23	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−1,450 sh	$18.00	−$26.1K	51,776
2026-06-23	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,450 sh	—	—	116,871
2026-06-23	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,450 sh	$8.04	+$11.7K	53,226
2026-06-16	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.8K sh	—	—	21,781
2026-06-10	AVTXAvalo Therapeutics, Inc.F Tax Payment	Chief Medical Officer	FTax Payment	−1,084 sh	$13.10	−$14.2K	51,776
2026-05-28	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+679 sh	$8.04	+$5,459.16	47,801
2026-05-28	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−679 sh	—	—	118,321
2026-05-28	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−679 sh	$16.00	−$10.9K	47,122
2026-05-21	AVTXAvalo Therapeutics, Inc.A Award	Chief Medical Officer	AAward	+43.5K sh	—	—	47,122
2026-05-15	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,000 sh	—	—	128,625
2026-05-15	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,000 sh	$12.65	+$38K	6,622
2026-05-15	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−3,000 sh	$18.76	−$56.3K	3,622
2026-05-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−27.5K sh	$18.03	−$496K	82,639
2026-05-06	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+28.7K sh	$8.04	+$230K	110,177
2026-05-06	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+77.9K sh	$12.65	+$985K	81,527
2026-05-06	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−28.7K sh	—	—	119,000
2026-05-06	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−77.9K sh	—	—	131,625
2026-05-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−10.1K sh	$22.88	−$230K	3,622
2026-05-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−19K sh	$22.41	−$426K	13,680
2026-05-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−44.9K sh	$21.20	−$953K	32,695
2026-05-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−5,000 sh	$19.65	−$98.3K	77,639
2026-05-05	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+679 sh	$8.04	+$5,459.16	5,301
2026-05-05	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−679 sh	—	—	147,650
2026-05-05	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,000 sh	—	—	209,530
2026-05-05	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−1,679 sh	$16.00	−$26.9K	3,622
2026-05-05	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,000 sh	$12.65	+$12.7K	4,622
2026-04-06	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−3,970 sh	$18.01	−$71.5K	3,622
2026-04-06	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,970 sh	—	—	210,530
2026-04-06	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,970 sh	$12.65	+$50.2K	7,592
2026-04-01	AVTXAvalo Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−679 sh	$16.00	−$10.9K	3,622
2026-04-01	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−679 sh	—	—	148,329
2026-04-01	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+679 sh	$8.04	+$5,459.16	4,301
2026-03-16	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+5,992 sh	$8.04	+$48.2K	29,114

Recent filings

Accepted (ET)
Sep 14
Doyle Mittie0001918845-26-000031
SEC(opens sec.gov)
Aug 194
Doyle Mittie0001918845-26-000029
SEC(opens sec.gov)
Aug 124
Doyle Mittie0001918845-26-000026
SEC(opens sec.gov)
Jul 294
Doyle Mittie0001918845-26-000024
SEC(opens sec.gov)
Jul 24
Doyle Mittie0001918845-26-000022
SEC(opens sec.gov)
Jun 254
Doyle Mittie0001918845-26-000020
SEC(opens sec.gov)

Companies

Address

C/O AVALO THERAPEUTICS, INC. 1500 LIBERTY RIDGE DRIVE, SUITE 321

WAYNE, PA, 19087